Cover Image
Market Research Report

Global Travel Vaccines Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 325833
Published Content info 118 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Travel Vaccines Market 2018-2022
Published: December 6, 2018 Content info: 118 Pages
Description

About this market:

Increased incidence of travel-related diseases is expected to drive the market growth. Traveling is often associated with higher health risks especially regarding infectious diseases. Thus, the rising incidence of travel related diseases will lead to more investments in the global travel vaccines market for the development of more effective vaccines. Technavio's analysts have predicted that the travel vaccines market will register a CAGR of almost 10% by 2022.

Market Overview:

Increase in global travel and migration

With the rise in traveling over the past few years has resulted in the spread of pathogens and disease-causing vectors worldwide. The increase in travel and migration offers huge opportunities to the manufacturers to invest in the R&D of new and more effective vaccines.

High cost of travel vaccinations

Travel clinics offer vaccinations at a slightly higher price and new vaccines are usually more expensive.

For the detailed list of factors that will drive and challenge the growth of the travel vaccines market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Sanofi and Valneva the competitive environment is quite intense. Factors such as the increased incidence of travel-related diseases and the increase in global travel and migration, will provide considerable growth opportunities to travel vaccines manufactures. GlaxoSmithKline, Pfizer, Sanofi, and Valneva are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR22195

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY TARGET DISEASE FOR IMMUNIZATION

  • Segmentation by target disease for immunization
  • Comparison by target disease for immunization
  • Influenza - Market size and forecast 2017-2022
  • Diphtheria - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Hepatitis - Market size and forecast 2017-2022
  • Typhoid - Market size and forecast 2017-2022
  • Polio - Market size and forecast 2017-2022
  • Yellow fever - Market size and forecast 2017-2022
  • Market opportunity by target disease

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity by region

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Changes in the demographic profile of travelers globally
  • Increased incidence of travel-related diseases
  • Initiatives by governments and other organizations to ensure travel safety
  • Evolving epidemiological patterns of infectious diseases in different countries

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Valneva

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global human vaccines market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline Vaccines Under Phase III Development
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Target disease for immunization - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by target disease for immunization
  • Exhibit 21: Influenza - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: Influenza - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: Diphtheria - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: Diphtheria - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Others - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 26: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Hepatitis - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 28: Hepatitis - Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Typhoid - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 30: Typhoid - Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Polio - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 32: Polio - Year-over-year growth 2018-2022 (%)
  • Exhibit 33: Yellow fever - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 34: Yellow fever - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Market opportunity by target disease for immunization
  • Exhibit 36: Customer landscape
  • Exhibit 37: Global - Market share by geography 2017-2022 (%)
  • Exhibit 38: Regional comparison
  • Exhibit 39: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 40: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 41: Top 3 countries in Americas
  • Exhibit 42: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 43: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 44: Top 3 countries in EMEA
  • Exhibit 45: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 46: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 47: Top 3 countries in APAC
  • Exhibit 48: Market opportunity
  • Exhibit 49: Vendor landscape
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Vendors covered
  • Exhibit 52: Vendor classification
  • Exhibit 53: Market positioning of vendors
  • Exhibit 54: GlaxoSmithKline - Overview
  • Exhibit 55: GlaxoSmithKline - Business segments
  • Exhibit 56: GlaxoSmithKline - Organizational developments
  • Exhibit 57: GlaxoSmithKline - Geographic focus
  • Exhibit 58: GlaxoSmithKline - Segment focus
  • Exhibit 59: GlaxoSmithKline - Key offerings
  • Exhibit 60: Pfizer - Overview
  • Exhibit 61: Pfizer - Business segments
  • Exhibit 62: Pfizer - Organizational developments
  • Exhibit 63: Pfizer - Geographic focus
  • Exhibit 64: Pfizer - Segment focus
  • Exhibit 65: Pfizer - Key offerings
  • Exhibit 66: Sanofi - Overview
  • Exhibit 67: Sanofi - Business segments
  • Exhibit 68: Sanofi - Organizational developments
  • Exhibit 69: Sanofi - Geographic focus
  • Exhibit 70: Sanofi - Segment focus
  • Exhibit 71: Sanofi - Key offerings
  • Exhibit 72: Valneva - Overview
  • Exhibit 73: Valneva- Business segments
  • Exhibit 74: Valneva - Organizational developments
  • Exhibit 75: Valneva - Geographic focus
  • Exhibit 76: Valneva - Key offerings
Back to Top